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We read with interest Arshad et al.’s thoughts on our guidance,
which was made available to and revised in response to feedback
from clinicians from the outset of the COVID-19 pandemic.1,2 We
note that the authors have not commented on any specific aspect of
the article’s content; instead proffering their appraisal of the authors,
coupled with a call for business as usual alongside an inference that
amidst an unprecedented pivot in NHS care towards patients with
COVID-19 at a time when up to a fifth of medical staff were off work,
such guidance was redundant.3–7 The in-excess of 2200 downloads
of, and over 400 visits to, the treatment protocols and webpages
respectively associated with this guidance suggest such conjecture
to be erroneous, but we fully dissect their multiple assumptions in
turn here.8
Firstly, Arshad et al. highlight that though the authorship is
geographically broad, it does not include representation from
colleagues typically involved in the diagnosis or palliation of patients
with pancreatic cancer. The article is explicit in defining its scope as
extending to areas in which the safe treatment of patients with
pancreatic cancer during the first or any subsequent peaks in
COVID-19 incidence might be impeded. Additional domains, such as
those relating to diagnosis and for which we would entirely agree
additional representation would be required, have been outlined in
detail elsewhere.9–13 Arshad et al. may be reassured that there are
no fewer than seven references to guidance provided by other
professional groups within the paper to reflect this.
Secondly, Arshad et al. seek to define the extent to which the
wider pancreatic cancer community have been consulted with
respect to the guidance. As is detailed within the manuscript,
feedback was provided by patient and public representatives via the
charity, Pancreatic Cancer UK. A broader initiative, run as part of
the patient-facing Pancreatic Cancer during COVID-19 (PCC) network
to which these authors have contributed and supported, saw the
guidance discussed and opened for feedback within at least two of
twelve COVID-19-focussed webinars that have been attended by a
majority of major surgical and non-surgical UK pancreatic cancer
treatment centres. Further substantial representation was achieved
at pace at the height of an evolving pandemic through the
establishment of a dedicated website (www.uppergicancer.com), via
participation in an online forum convened by the Royal College of
Radiologists (RCR) and via the initiation of a peer-support
mechanism for clinicians seeking advice on treatment decisions
for patients with pancreatic cancer. Quite in contrast to Arshad
et al.’s speculation, the culminating manuscript was peer-reviewed,
much like any other, and is published online to allow for critique
such as that we are responding to here.
Thirdly, Arshad and colleagues query the methodology used in
the development of the guidance and the potential for a
‘predominance of clinical oncologists’ in the authorship to have
resulted in ‘excess detail on the radiation oncology management
in the paper’. Less than 15% (316 words) of the paper’s 2390
words focus on the radiation-based management of pancreatic
cancer, which is hardly a ‘singular feature’. Further, and as Arshad
and colleagues are presumably aware, there is no specialty of
radiation oncology in the UK and as such 15 of the 18 authors are
trained and have experience of the systemic therapies to which
the bulk of the article relates. We are then unsure of the accuracy
of the metrics on which Arshad and his four colleagues have
relied. In fact, where radiation is discussed it is almost universally
with respect to the use of hypo-fractionated regimens, a
treatment approach that has been widely supported across the
world during the pandemic.14,15
Fourthly, and turning to its formation, we agree with Arshad et al.
that constrained by a need to urgently provide clinicians with
guidance, we were not able to fully align our methodology with
gold standard practice, and that it is possible that another eighteen
authors may have proposed alternative guidance. However, we are
not aware of—and we note that Arshad and colleagues have not
provided—such an alternative. Further, whilst we agree and indeed
highlight in the manuscript that thankfully ‘many sites had very little
disruption… even at the height of the pandemic’, the obvious
corollary is that many did face significant disruption.
Thus, we agree with Arshad et al. that as the first pandemic peak
subsides there is now ‘no reason why the management of pancreas
cancer should be different’, excepting the testing and distancing
measures outlined by Arshad and colleagues that make this
possible. However, the utility of our guidance for clinicians who
grappled with maintaining pancreatic cancer treatments in the
absence of these very measures and in the midst of swingeing
restrictions to NHS services is made clear here, as are our significant
efforts to engage at pace with the pancreatic cancer community.
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